SCHEMBL2358895

SCHEMBL2358895

CC(C)(F)C(=O)CC(=O)c1ccc(F)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLOD2 O00469 2/20 0.76
NPC1 O15118 4/20 0.52
RAB9A P51151 3/20 0.52
PTPN1 P18031 2/20 0.52
HTR7 P34969 1/20 0.50
MAPT P10636 3/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
ALOX12 P18054 2/20 0.49
HTT P42858 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
HPGD P15428 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
PLOD3 O60568 1/20 0.49
PLOD1 Q02809 1/20 0.49
LMNA P02545 1/20 0.47
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
KDM4E B2RXH2 1/20 0.44
USP2 O75604 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19919802 0.89 PLOD2 (0.70) PLOD2NPC1RAB9APTPN1HTR7
SCHEMBL711849 0.86 PLOD2 (1.00) PLOD2NPC1RAB9APTPN1HTR7
SCHEMBL4599899 0.83 PLOD2 (0.73) PLOD2NPC1RAB9APTPN1HTR7
SCHEMBL2491432 0.81 PLOD2 (0.69) PLOD2NPC1RAB9APTPN1HTR7
SCHEMBL13550716 0.79 NPC1 (0.71) PLOD2NPC1RAB9APTPN1HTR7
SCHEMBL7798057 0.79 PLOD2 (0.68) PLOD2NPC1RAB9APTPN1HTR7
SCHEMBL120769 0.78 PLOD2 (0.60) PLOD2NPC1RAB9APTPN1HTR7
SCHEMBL9483687 0.77 PLOD2 (0.53) PLOD2NPC1RAB9APTPN1MAPT
SCHEMBL29025694 0.77 PLOD2 (0.54) PLOD2NPC1RAB9APTPN1HTR7
SCHEMBL11989218 0.76 NPC1 (0.55) PLOD2NPC1RAB9APTPN1HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703761-B2 Organic compounds NOVARTIS AG (CH) 2014-04-22 US disclosed
EP-2559455-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2013-02-20 EP disclosed
EP-2548618-A2 Organic compounds Novartis AG (CH) 2013-01-23 EP disclosed
EP-2380631-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2011-10-26 EP disclosed
EP-2349484-A2 HETEROARYL DERIVATIVES AS DGAT1 INHIBITORS Novartis AG (CH) 2011-08-03 EP disclosed
US-20100022513-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-28 US disclosed
WO-2010007046-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022513-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 PLOD2 1133/4885NPC1 83/4885RAB9A 2469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.